{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "In a presidential race whose outcome is expected to hang on turnout at the polls, an army of interest groups is pumping at least $350 million into get-out-the-vote campaigns that are rewriting the tactics of elections. The efforts are part of the most expensive voter-drive ground war in history. It includes the major parties and their allies, the independent but partisan groups known as 527's, whose attack advertisements have played a big role in both President Bush's and Senator John Kerry's campaigns.", "headline": {"main": "Interest Groups Mounting Costly Push to Get Out Vote", "kicker": "THE 2004 CAMPAIGN: ADVOCACY GROUPS"}, "abstract": "Interest groups are pumping at least $350 million into most expensive get-out-the-vote campaigns ever; organizations include major parties, 527 advocacy groups and, for first time, hundreds of civic groups and deep-pocketed business interests such as US Chamber of Commerce; onslaught of door-to-door drives, e-mailings and telephone calls is heaviest in swing states like Florida; photos; fervor reaches Baghdad, where Republican lobbyist is trying to help American contract workers vote in time; nonpartisan groups are not required to say where funds come from and cannot promote candidate without jeopardizing tax status, although they can emphasize 'hot button' issues for targeted audiences; new National Voice charity coalition is spending $80 million to motivate John Kerry voters and Chamber of Commerce targets Pres Bush's supporters; voters says they enjoy attention but fear loss of privacy and do not like being pressured to vote absentee by political operatives who are even gathering completed ballots in swing states (M)", "print_page": "1", "word_count": 2065, "_id": "4fd280208eb7c8105d84af89", "snippet": "An army of nonpartisan groups, not bound by federal election law, is pumping millions into get-out-the-vote campaigns.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/20/politics/campaign/20vote.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "BUSH, GEORGE W"}, {"name": "persons", "value": "KERRY, JOHN"}, {"name": "glocations", "value": "IRAQ"}, {"name": "glocations", "value": "BAGHDAD (IRAQ)"}, {"name": "glocations", "value": "FLORIDA"}, {"name": "organizations", "value": "UNITED STATES CHAMBER OF COMMERCE"}, {"name": "organizations", "value": "NATIONAL CHOICE"}, {"name": "subject", "value": "PRESIDENTIAL ELECTIONS (US)"}, {"name": "subject", "value": "STATES (US)"}, {"name": "subject", "value": "VOTING REQUIREMENTS AND VOTERS"}, {"name": "subject", "value": "FINANCES"}, {"name": "subject", "value": "TELEPHONES AND TELECOMMUNICATIONS"}, {"name": "subject", "value": "ABSENTEE VOTING"}, {"name": "subject", "value": "COMPUTERS AND THE INTERNET"}, {"name": "subject", "value": "PRESIDENTIAL ELECTION OF 2004"}, {"name": "subject", "value": "UNITED STATES ARMAMENT AND DEFENSE"}, {"name": "subject", "value": "PRIVACY"}, {"name": "subject", "value": "UNITED STATES INTERNATIONAL RELATIONS"}, {"name": "subject", "value": "ELECTRONIC MAIL"}, {"name": "subject", "value": "VOTING REQUIREMENTS"}, {"name": "subject", "value": "ELECTIONS"}, {"name": "subject", "value": "LOBBYING AND LOBBYISTS"}, {"name": "subject", "value": "TERRORISM"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Michael", "rank": 1, "lastname": "MOSS"}, {"organization": "", "role": "reported", "firstname": "Ford", "rank": 2, "lastname": "FESSENDEN"}], "original": "By MICHAEL MOSS and FORD FESSENDEN; Alexis Rehrmann contributed reporting for this article"}, "document_type": "article", "pub_date": "2004-10-20T00:00:00Z", "section_name": "Technology; Front Page; U.S.; Washington"}, {"type_of_material": "An Analysis; News Analysis", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Less than three weeks after Merck withdrew its arthritis painkiller Vioxx from the market because it increased the risk of heart attacks, Pfizer announced plans yesterday to test if its best-selling painkiller Celebrex, which is in the same class of drugs as Vioxx, can do the opposite -- help prevent heart attacks. But Pfizer's announcement is raising questions.", "headline": {"main": "A New Trial of Celebrex, and Questions on Its Timing", "kicker": "News Analysis"}, "abstract": "Analysis of Pfizer Inc's plans to test if its best-selling painkiller Celebrex, which is same class of drugs as Merck & Co's drug Vioxx, which has been recalled, can help prevent heart attacks; says Pfizer's announcement is raising questions since Pfizer warned on Oct 15 that Bextra, another of its drugs in same class as Vioxx and Celebrex, increases risks of heart attack and stroke in patients undergoing coronary-bypass surgery; adds timing of announcement of new Celebrex trial could divert attention from warning about Bextra; holds another question is whether new trial would be ethical and able to attract participants, given problems associated with Vioxx and with Bextra (M)", "print_page": "1", "word_count": 1158, "_id": "4fd23f1a8eb7c8105d7d5fcf", "snippet": "Pfizer said that it would sponsor a major clinical trial of Celebrex, its prescription arthritis pain medication, to assess the cardiovascular benefits of the drug.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/19/business/19drug.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "MERCK & CO INC"}, {"name": "organizations", "value": "PFIZER INC"}, {"name": "organizations", "value": "MERCK & COMPANY INCORPORATED"}, {"name": "organizations", "value": "PFIZER INCORPORATED"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "CELEBREX (DRUG)"}, {"name": "subject", "value": "BEXTRA (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "ARTHRITIS AND RHEUMATISM"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "RECALLS AND BANS OF PRODUCTS"}, {"name": "subject", "value": "VIOXX (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Andrew", "rank": 1, "lastname": "POLLACK"}], "original": "By ANDREW POLLACK"}, "document_type": "article", "pub_date": "2004-10-19T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "THE issue of advertising prescription drugs directly to consumers is at the heart of a lawsuit filed yesterday against the pharmaceutical giant AstraZeneca by a coalition of consumer activists representing labor, retired workers and the elderly. The lawsuit, filed in a state court in Los Angeles, takes on a familiar target -- the decision by AstraZeneca in 2001 to introduce one drug, Nexium, to replace another, Prilosec, as the patent protection for Prilosec was expiring.", "headline": {"main": "Taking aim at ads for the purple pill, a lawsuit says the selling of Nexium is costing society billions.", "kicker": "THE MEDIA BUSINESS: ADVERTISING"}, "abstract": "Issue of advertising prescription drugs directly to consumers is at heart of lawsuit filed against AstraZeneca by coalition of consumer activists representing labor, retired workers and elderly; lawsuit takes on familiar target--decision of AstraZeneca in 2001 to introduce drug Nexium to replace Prilosec as patent protection for Priolsec was expiring; new element is claim that billions of dollars subsequently spent by AstraZeneca on advertising, promotions and other marketing persuaded consumers to shun much cheaper alternatives like generic drugs and Priolsec in its over-the-counter iteration by wrongfully presenting Nexium as more effective in treating acid reflux; Steven W Berman of law firm Hagens Berman, which filed lawsuit, says advertising was deceptive; photo (M)", "print_page": "4", "word_count": 896, "_id": "4fd25a618eb7c8105d806b62", "snippet": "A coalition of consumer activists filed suit against AstraZeneca, claiming that its marketing of the drug Nexium for acid reflux was deceptive.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/19/business/media/19adco.html", "multimedia": [{"url": "images/2004/10/19/business/19adco.gif", "subtype": "thumbnail", "legacy": {"hasthumbnail": "Y", "thumbnailheight": 75, "thumbnail": "images/2004/10/19/business/19adco.gif"}, "type": "image", "height": 75}], "subsection_name": null, "keywords": [{"name": "creative_works", "value": "ADVERTISING (TIMES COLUMN)"}, {"name": "persons", "value": "BERMAN, STEVEN W"}, {"name": "organizations", "value": "ASTRAZENECA"}, {"name": "organizations", "value": "HAGENS BERMAN OF SEATTLE"}, {"name": "subject", "value": "HEARTBURN"}, {"name": "subject", "value": "NEXIUM (DRUG)"}, {"name": "subject", "value": "ADVERTISING"}, {"name": "subject", "value": "MARKETING AND MERCHANDISING"}, {"name": "subject", "value": "MISLEADING AND DECEPTIVE ADVERTISING"}, {"name": "subject", "value": "ADVERTISING AND MARKETING"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "ETHICS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "INVENTIONS AND PATENTS"}, {"name": "subject", "value": "PRILOSEC (DRUG)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Stuart", "rank": 1, "lastname": "Elliott"}], "original": "By Stuart Elliott"}, "document_type": "article", "pub_date": "2004-10-19T00:00:00Z", "section_name": "Technology; Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Health & Fitness", "lead_paragraph": "In surveys and focus groups, most Americans say they know what to do to protect themselves against osteoporosis, the disease of fragile bones that often occurs in the elderly: eat lots of calcium-rich foods or take a calcium supplement. Many say they are doing just that, or plan to.", "headline": {"main": "The (Often Neglected) Basics for Keeping Bones Healthy"}, "abstract": "Recent Surgeon General report on bone health cites disconnect between information on bone disease and action of medical community to reduce osteoporosis; Dr Joan McGowan, National Institute of Arthritis and Musculoskeletal and Skin Diseases chief and co-editor of report, holds that doctors do not adequately investigate fractures or perform needed tests to discover bone density problems; report recommendations and importance of vitamin D in bone health discussed; drawing (M)", "print_page": "6", "word_count": 1040, "_id": "4fd25a618eb7c8105d806b5f", "snippet": "Doctors are saying that the lack of knowledge about preventing bone disease often leads to bad practice.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/19/health/19bone.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "MCGOWAN, JOAN"}, {"name": "organizations", "value": "NATIONAL INSTITUTE OF ARTHRITIS"}, {"name": "subject", "value": "VITAMIN D"}, {"name": "subject", "value": "BONES"}, {"name": "subject", "value": "VITAMINS"}, {"name": "subject", "value": "SURGEON GENERAL (US)"}, {"name": "subject", "value": "DOCTORS"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "RESEARCH"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "OSTEOPOROSIS"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gina", "rank": 1, "lastname": "KOLATA"}], "original": "By GINA KOLATA"}, "document_type": "article", "pub_date": "2004-10-19T00:00:00Z", "section_name": "Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Arts and Leisure Desk", "lead_paragraph": "RUTH ANN McCLAIN, a flutist from Memphis, used to suffer from debilitating onstage jitters. ''My hands were so cold and wet, I thought I'd drop my flute,'' Ms. McClain said recently, remembering a performance at the National Flute Convention in the late 1980's. Her heart thumped loudly in her chest, she added; her mind would not focus, and her head felt as if it were on fire. She tried to hide her nervousness, but her quivering lips kept her from performing with sensitivity and nuance.", "headline": {"main": "Better Playing Through Chemistry"}, "abstract": "Blair Tindall article on growing concerns for use of anxiety-quelling beta blockers among classical music performers; says one of most commonly prescribed drugs is propranolol, Wyeth drug sold under brand name Inderal; holds flautist Ruth Ann McClain, whose career was saved by use of propranolol, was fired by Rhodes College for recommending medication to adult students afflicted with performance anxiety; controversy over whether musicians should be tested for drugs such as athletes discussed; photos (M) of beta blocking drugs; photos (L)", "print_page": "1", "word_count": 2155, "_id": "4fd247f58eb7c8105d7e4087", "snippet": "Beta blockers, which can quell anxiety, have become nearly ubiquitous in the classical music world. Are the drugs a godsend or a crutch?", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/17/arts/music/17tind.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "MCCLAIN, RUTH ANN"}, {"name": "organizations", "value": "RHODES COLLEGE"}, {"name": "organizations", "value": "WYETH"}, {"name": "subject", "value": "PROPRANOLOL (DRUG)"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "MUSIC"}, {"name": "subject", "value": "CLASSICAL MUSIC"}, {"name": "subject", "value": "INDERAL SA (DRUG)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "STRESS (HUMAN)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "TESTS AND TESTING"}, {"name": "subject", "value": "BETA BLOCKERS"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Blair", "rank": 1, "lastname": "TINDALL"}], "original": "By BLAIR TINDALL"}, "document_type": "article", "pub_date": "2004-10-17T00:00:00Z", "section_name": "Arts; Health"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "A customer at the Concourse Drugs pharmacy in the Bronx will pay about $118 for a month's supply of 20-milligram Lipitor. At PharmacyinCanada.com, a Canadian online outlet, the same quantity of the drug, Pfizer's cholesterol-lowering medication, costs $79. The difference has become a tempting political target. Senator John Kerry, the Democratic presidential candidate, has made a campaign pledge to help cut Americans' prescription drug costs by allowing them to import drugs from Canada. President Bush has conceded that the idea is worth a try ''if there's a safe way to do it.'' Bipartisan legislation in Congress would allow the reimportation of prescription drugs from Canada and other industrialized countries.", "headline": {"main": "Importing Less Expensive Drugs Not Seen as Cure for U.S. Woes"}, "abstract": null, "print_page": "1", "word_count": 1354, "_id": "4fd259c18eb7c8105d806326", "snippet": "Experts say that importing drugs from countries that control their prices would not make drugs cheaper in the U.S.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2004/10/16/business/16drug.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "CANADA"}, {"name": "subject", "value": "PRESIDENTIAL ELECTIONS (US)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Eduardo", "rank": 1, "lastname": "PORTER"}], "original": "By EDUARDO PORTER"}, "document_type": "article", "pub_date": "2004-10-16T00:00:00Z", "section_name": "Front Page; Health; Business"}, {"type_of_material": "Summary", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Importing Canadian Drugs Might Not Lower Prices Many economists and health care experts say that importing drugs from countries like Canada that control their prices would do little to solve the problem of expensive drugs in the United States. The nonpartisan Congressional Budget Office has said that allowing Canadian drug imports would have a negligible effect on costs. And drug makers say they would simply reduce their shipments to distributors in the countries supplying the drugs. [Page A1.] No Deal on Russia-China Pipeline Russia and China failed to seal an agreement on a proposed gas pipeline from eastern Siberia to northern China. President Vladimir V. Putin, left, of Russia visited China this week amid hopes that a deal was near. Instead, the two countries signed a loose agreement that left the door open to future talks. Many said the two countries remain wary neighbors. [C3.] Layoffs and Write-Down at Sprint Sprint plans to lay off 700 sales representatives and write down the value of its network to reflect the eroding market for traditional phone services. The company has already eliminated 7,500 positions this year. [C2.] Delta Expects a Large Loss Delta Air Lines said that it expected to lose as much as $675 million for the third quarter, renewing speculation that it could seek bankruptcy protection later this month. [C12.] Greenspan Eases Fears on Oil Alan Greenspan said higher oil costs had hurt the gross domestic product this year, but he said the long-term outlook for global oil supplies was reassuring. Crude oil prices climbed 17 cents, to $54.93 a barrel. [C4.] British Bankers Face Extradition A judge ruled that three British bankers can be extradited to the United States to face charges of wire fraud related to off-balance-sheet dealings with Enron. [C3.] Retail Sales Surged in September A large increase in September retail sales and gains in producer prices indicated stronger economic growth. But a surprisingly soft reading on consumer confidence showed that high oil prices were a threat. [C3.] Economic Reports Lift Stocks Stocks rebounded as a retail sales report showed that higher oil prices were not keeping consumers from spending. The Standard & Poor's 500-stock index rose 4.91 points, to 1,108.20, and the Dow Jones industrial average rose 38.93 points, to 9,933.38. [C4.] Judge to Decide Fate of Oracle Bid The two-week trial to decide the fate of Oracle's $7.7 billion hostile tender offer for PeopleSoft moved to the judge, who said the parties had moved closer together. [C2.] Warning Labels on Antidepressants The Food and Drug Administration ordered pharmaceutical companies to add strong warnings to antidepressants, saying the drugs can cause suicidal thoughts and actions in children and teenagers. [A9.] Inquiry on Bonds at Bear Stearns Bear Stearns said it had received subpoenas from federal investigators looking into its municipal bond business. [C12.] Bitumen Price-Fixing Charges The European Commission plans to file charges against several companies for fixing the price of bitumen, an oil-based product used in making houses and road surfaces. [C3.] Flu Vaccine Not Salvageable None of the flu vaccine made by Chiron that was quarantined in Britain is safe for Americans to use, federal health officials said. [A14]", "headline": {"main": "BUSINESS DIGEST"}, "abstract": null, "print_page": "1", "word_count": 525, "_id": "4fd25a618eb7c8105d806b33", "snippet": "Importing Canadian Drugs Might Not Lower Prices  Many economists and health care experts say that importing drugs from countries like Canada that control their prices would do little to solve the problem of expensive drugs in the United States.    ...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://query.nytimes.com/gst/fullpage.html?res=9505E4DA143AF935A25753C1A9629C8B63", "multimedia": [], "subsection_name": null, "keywords": [], "byline": null, "document_type": "article", "pub_date": "2004-10-16T00:00:00Z", "section_name": "Business"}], "meta": {"hits": 7, "offset": 0, "time": 52}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}